The GHRH antagonist MZ-J-7-114 was shown to block the activities of VEGF and downregulate the expression of epidermal growth factor (EGF) and VEGF receptors, thereby effectively abolishing angiogenesis and tumor growth [5]. Here, EGF is linked to neoplasm.